Xiaoyan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoyan Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Bo Bi
School of Pharmacy, Changchun University of Chinese Medicine, Changchun, Jilin 130117, China
1 shared publicationBoyuan Liu
Academy of Traditional Chinese Medicine, Jilin Agricultural Science and Technology University, Jilin, China
1 shared publication- Haiying Bao
Key Laboratory for Development and Utilization of Fungi Traditional Chinese Medicine Resources, Jilin Agricultural University, Changchun 130118, China; Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang 330115, China; College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China
1 shared publication Jiaxin Zhang
Academy of Traditional Chinese Medicine, Jilin Agricultural Science and Technology University, Jilin, China
1 shared publication- Jingshan Bao
College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, China
1 shared publication Junsen Qin
Academy of Traditional Chinese Medicine, Jilin Agricultural Science and Technology University, Jilin, China
1 shared publication
Latest Publications
- Open Access
- 16 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1653035
Integrated gut microbiota and metabolomics analysis reveals the antitumor effects of ergosta-4,6,8(14),22-tetraen-3-one purified from the medicinal fungus pholiota adiposa in tumor-bearing mice
Objective: This study aims to investigate the antitumour mechanism of ergosta-4,6,8(14),22-tetraen-3-one (ETO), extracted from Pholiota adiposa, in H22 tumour-bearing mice through integrated metabolomics and gut microbiota systems analysis. Methods: After establishing the H22 tumor mouse model, we performed serum metabolomics through nontargeted UHPLC-HRMS and conducted gut microbiota profiling. Result: ETO exhibited significant antitumor effects, with tumor inhibition rates of 59.74% (low dose) and 76.10% (high dose).Untargeted metabolomics revealed that molecules downstream of the tricarboxylic acid cycle, arachidonic acid and linoleic acid were upregulated. Gut microbiota analysis revealed ETO-mediated enrichment of beneficial bacteria (Firmicutes and Lactobacillus) and suppression of the harmful bacterial species Bartonella. Integrative analysis demonstrated a negative correlation between indole-3-acetonitrile and Bartonella. Conclusion: ETO can inhibit the growth of tumor cells, and its effect on liver and kidney damage is less than that of CTX. Linoleate, and L-tryptophan emerged as potential therapeutic targets, while Firmicutes and Lactobacillus enrichment suggests gut microbiota-mediated antitumor activity, providing novel insights for hepatocellular carcinoma treatment.
- 16 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1653035
Open AccessIntegrated gut microbiota and metabolomics analysis reveals the antitumor effects of ergosta-4,6,8(14),22-tetraen-3-one purified from the medicinal fungus pholiota adiposa in tumor-bearing mice
Objective: This study aims to investigate the antitumour mechanism of ergosta-4,6,8(14),22-tetraen-3-one (ETO), extracted from Pholiota adiposa, in H22 tumour-bearing mice through integrated metabolomics and gut microbiota systems analysis. Methods: After establishing the H22 tumor mouse model, we performed serum metabolomics through nontargeted UHPLC-HRMS and conducted gut microbiota profiling. Result: ETO exhibited significant antitumor effects, with tumor inhibition rates of 59.74% (low dose) and 76.10% (high dose).Untargeted metabolomics revealed that molecules downstream of the tricarboxylic acid cycle, arachidonic acid and linoleic acid were upregulated. Gut microbiota analysis revealed ETO-mediated enrichment of beneficial bacteria (Firmicutes and Lactobacillus) and suppression of the harmful bacterial species Bartonella. Integrative analysis demonstrated a negative correlation between indole-3-acetonitrile and Bartonella. Conclusion: ETO can inhibit the growth of tumor cells, and its effect on liver and kidney damage is less than that of CTX. Linoleate, and L-tryptophan emerged as potential therapeutic targets, while Firmicutes and Lactobacillus enrichment suggests gut microbiota-mediated antitumor activity, providing novel insights for hepatocellular carcinoma treatment.
- 4 November 2025
- Published by Elsevier in Fitoterapia
- Vol. 188, 106965
Jacobaeae Herba (from Jacobaea cannabifolia and Jacobaea litvinovii): A review of botany, traditional uses, phytochemistry, pharmacology, and toxicology
- 4 November 2025
- Published by Elsevier in Fitoterapia
- Vol. 188, 106965
Jacobaeae Herba (from Jacobaea cannabifolia and Jacobaea litvinovii): A review of botany, traditional uses, phytochemistry, pharmacology, and toxicology